You must be aged 21 or older to visit the website.
TORONTO, ONTARIO – August 13, 2020
Flora Growth Corp. is pleased to provide the market with a comprehensive update on its current Regulation A+ Tier 2 offering and public listing strategy.
“Despite conducting this raise in the middle of the COVID-19 pandemic, we have seen incredible success to date,” commented Flora Growth’s CEO, Damian Lopez. “We believe this speaks to the strength of the Flora Growth story. Looking forward, exciting days are ahead for Flora investors; we have secured enough funding to execute on our vision for the company and are now preparing to close the offering and go public.”
About Flora Growth’s Regulation A+ Offering
Flora Growth’s Regulation A+ offering has been open for 7 months out of a maximum of 12 months. During that period, Flora has raised US$14.8 million and continues to work towards the potential maximum raise of US$30 million.
While Flora still continues to see strong investment inflow, Flora expects to close the offering on August 21, 2020 as sufficient capital has been secured to execute on its immediate business plans. At this time, Flora anticipates using any additional capital to accelerate its growth and generate returns for all investors.
The use of funds from Flora’s Regulation A+ offering includes capital expenditures at the Cosechemos and Breeze Laboratory divisions, sales and marketing for Flora’s new brand portfolio, and general corporate and working capital provisions.
Upon closing of the offering, Flora intends to consider listing its shares on an American exchange such as the NASDAQ or NYSE, at a time that maximizes shareholder value.
About Flora Growth’s OTC Ticker Symbol
Flora has engaged Glendale Securities Inc. (“Glendale”) to file a Form 211 application with FINRA to initiate quotations on OTC markets in the United States and to secure an OTC ticker symbol for that purpose (the “Symbol”). Upon closing of the Regulation A+ offering and obtaining necessary approvals from FINRA, Flora’s shares are expected to become cleared for quotation and trading on OTC markets and Flora’s shares will be assigned the Symbol.
To make an investment in Flora Growth, go to www.investflora.com
For information on making an investment, contact:
Flora Growth Investments Team
Availability: 9 am to 7 pm ET
Flora Growth Corp.
Flora Growth is a vertically integrated cannabis company striving to be a globally recognized cannabis brand by leveraging low-cost production of cannabis to supply CBD oil to our portfolio of consumer and medical brands. Flora prioritizes organic ingredients and value-chain sustainability across its portfolio to create products that help consumers restore and thrive.
This news release may contain forward-looking statements. These statements include statements regarding the Company’s operations, Glendale’s filing of the Form 211 application, the approval by FINRA of the application and the assignment of the Symbol, and the Company’s strategy, and future plans and objectives, including closing the Regulation A+ offering early, using capital to accelerate Flora’s growth and generate returns for investors and publicly listing the Company’s shares on an American stock exchange. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially. We do not assume any obligation to update any forward-looking statements, except as required by applicable laws.
Interested in participating?
Be a part of our exciting future and participate in our Reg A+ offering.